Abstract W P147: Apixaban Versus Warfarin in Patients with Atrial Fibrillation: Patient Characteristics of the Latin America Cohort from a Multinational Clinical Trial

Introduction: Apixaban, a novel oral direct factor Xa inhibitor has clearly demonstrated clinical benefit in stroke or systemic embolism (SE) reduction without impacting the risk of major bleeding or intracranial hemorrhage in patients with atrial fibrillation (AF). Here we present the patient characteristics of the Latin American cohort (patients from Argentina, Brazil, Chile, Colombia, Mexico, Peru and Puerto Rico) relative to the overall clinical trial population. Methods: Patients with AF who also had at least one risk factor for stroke were randomized to receive apixaban (at a dose of 5 mg twice daily) or warfarin (target international normalized ratio, 2.0 to 3.0) in a double blind clinical trial. The study recruited from 39 countries from December 2006 through April 2010. Of the 36 countries seven were from the Latin America region: Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Puerto Rico. Patient characteristics from the Latin American (LA) cohort, is presented relative to the patient cha...